Zacks Investment Research·Jun 19, 2026
Bruker Gains 50.3% in a Year: What's Driving the Rally?BRKR's rally is fueled by BSI NANO growth, AI-driven metrology demand and gains in preclinical imaging despite tariff pressures.
Bruker Corporation(BRKR)Earnings, Financials & Key Ratios
BRKR•NASDAQ
$58.25
Price updated Jul 7, 2026
AboutBruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.Show more
- Revenue$3.44B+2.1%
- EBITDA$456M+4.4%
- Net Income-$9M-107.6%
- EPS (Diluted)-0.15-119.7%
- Gross Margin45.91%-6.3%
- EBITDA Margin13.28%+2.3%
- Operating Margin6.87%-8.7%
- Net Margin-0.25%-107.5%
- ROE-0.4%-105.7%
BRKR Price & Volume
Bruker Corporation (BRKR) stock price & volume — 10-year historical chart
Loading chart...
Aggressive Acquisition Strategy Strains Operating Margin Performance
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Strained
Financial:Strained
Cash Flow:Mixed
Primary Risk:Acquisition-driven margin dilution
Key Thesis Takeaways
- Bruker's pivot toward clinical diagnostics through acquisitions has resulted in significant earnings volatility and margin compression, with operating margins falling from 12.1% in 2023Q4 to 1.2% in 2026Q1.
- While the company maintains a presence in specialized scientific instrumentation, the reliance on debt-funded inorganic growth has inflated goodwill to $1.5 billion and obscured organic performance.
- Investors should monitor whether the company can stabilize its cash conversion and improve operational efficiency as revenue growth has decelerated to 2.7% in the most recent quarter.
Verdict Logic
the company's inability to maintain consistent profitability, highlighted by a net loss of $59.6 million in 2025Q3 and a current operating margin of only 1.2%, suggests significant integration risks remain.
BRKR Growth Metrics
Bruker Corporation (BRKR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.79%
5 Years11.57%
3 Years10.74%
TTM0.36%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-114.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-145.98%
Return on Capital
10 Years13.53%
5 Years11.9%
3 Years8.96%
Last Year4.97%
BRKR Recent Earnings
Bruker Corporation (BRKR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.31+34.8%
$0.23
Rev
$823M+3.5%
$796M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.59-9.2%
$0.65
Rev
$977M+1.6%
$962M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.60+81.8%
$0.33
Rev
$861M-10.8%
$965M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.32-3.0%
$0.33
Rev
$797M-1.6%
$810M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.31vs $0.23+34.8% | $823Mvs $796M+3.5% |
| Q1 2026 | Feb 12, 2026 | $0.59vs $0.65-9.2% | $977Mvs $962M+1.6% |
| Q4 2025 | Nov 3, 2025 | $0.60vs $0.33+81.8% | $861Mvs $965M-10.8% |
| Q3 2025 | Aug 4, 2025 | $0.32vs $0.33-3.0% | $797Mvs $810M-1.6% |
Based on last 12 quarters of dataView full earnings history →
Latest BRKR News
Recent stock market news and headlines for Bruker Corporation (BRKR)
Forbes·Jun 17, 2026
The Healthcare M&A WaveIn this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
GuruFocus·Jun 15, 2026
Bruker Corp (BRKR) Stock Up 4.4% and Still Undervalued -- GF Score: 85/100On June 15, 2026, Bruker Corp (BRKR) shares rose 4.4% to a current price of $56.63. The stock has shown remarkable performance within the past year, with a 48.7
Peers Comparison
Key metrics vs top competitors for Bruker Corporation (BRKR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $58.25 | $8.87B | -388.33 | 2.08% | -0.25% | -0.4% | 0.26% | |
| $374.93 | $24.44B | 34.84 | 6.99% | 11.91% | 8.04% | — | |
| $53.73 | $12.73B | 30.70 | -2.61% | 12.37% | 7.95% | — | |
| $62.55 | $19.26B | 35.95 | -17.48% | 11.48% | 7.38% | — | |
| $131.14 | $37.04B | 28.70 | 6.73% | 19.55% | 20.84% | — | |
| $516.62 | $191.99B | 29.12 | 3.91% | 15.18% | 13.23% | — |
Compare BRKR vs Peers
Bruker Corporation (BRKR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BRKR SEC Filings & Documents
Bruker Corporation (BRKR) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Apr 10, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when BRKR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BRKR Frequently Asked Questions
Bruker Corporation (BRKR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Bruker Corporation's revenue?
Bruker Corporation (BRKR) reported $3.46B in revenue for fiscal year 2025. This represents a 5246% increase from $64.7M in 1999.
How fast is Bruker Corporation growing?
Bruker Corporation (BRKR) grew revenue by 2.1% over the past year. Growth has been modest.
Is BRKR profitable?
Bruker Corporation (BRKR) reported a net loss of $11.6M for fiscal year 2025.
Dividend & Returns
Does BRKR pay dividends?
Yes, Bruker Corporation (BRKR) pays a dividend with a yield of 0.26%. This makes it attractive for income-focused investors.
What is BRKR's return on equity?
Bruker Corporation (BRKR) has a return on equity (ROE) of -0.4%. Negative ROE indicates the company is unprofitable.
What is Bruker Corporation's free cash flow?
Bruker Corporation (BRKR) generated $51.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.